The Mayo Clinic’s Mignonne Guy

You Don’t Want This Thorn in Your Side (And Don’t Chew Too Loudly in Her Presence, Either)

Mignonne Guy is a researcher at the Mayo Clinic Arizona. Before participating in a panel on closing the cancer mortality gap between blacks and whites, she explained in the Zócalo green room why if you know her or work with her, she’s probably the biggest thorn in your side—and why if you knew her years ago, you might be surprised to find out where she’s gotten and what she’s up to now.

Biologist Leticia Márquez-Magaña

A Health Researcher with a Passion for General Hospital

Leticia Márquez-Magaña is a biologist at San Francisco State University’s Health Institute for Practice, Research, and Policy. Before participating in a panel on race and cancer, she confessed her longtime …

Should Jerry Brown Just Ignore His Cancer?

Governor’s Choice of Radiation Therapy Could Cause More Harm Than Doing Nothing at All

As California’s oldest governor, Jerry Brown has gone out of his way to demonstrate his vigorous good health, jogging around the Capitol and even challenging reporters to pull-up contests—which he …

Can We Close the Mortality Gap?

Having Cancer Is Dangerous Enough—But Being Black With Cancer Is Even Deadlier

We don’t know exactly why African-Americans suffer disproportionately from cancer, with higher incidence, morbidity, and mortality rates than other groups. But we do know that many factors—social, environmental, behavioral, and …

Cancer Doesn’t Have to Be This Deadly For African-Americans

We Don’t Know All the Causes of Health Disparities Between Blacks and Whites. But We Can Still Remedy Some Obvious Problems.

Doctors and health experts have long known that members of minority groups in the United States tend to have poorer health outcomes than white Americans. I noticed it myself while …

The Equity Cancer

For All the Progress in Treating the Disease, Why Are So Many African-Americans Still Dying From It?

Talk to those who treat and study cancer, and you hear about progress in research and treatment. But there is a stubborn exception to the good news: the persistently higher …